ChloroquineV1, PubMed, Corpus, bibRecord, 000301

Rosiglitazone is a superior bronchodilator compared to chloroquine and β-adrenoceptor agonists in mouse lung slices.

Identifieur interne : 000301 ( PubMed/Corpus ); précédent : 000300; suivant : 000302

Rosiglitazone is a superior bronchodilator compared to chloroquine and β-adrenoceptor agonists in mouse lung slices.

Auteurs : Chantal Donovan ; Mirjam Simoons ; James Esposito ; Jean Ni Cheong ; Meaghan Fitzpatrick ; Jane Elizabeth Bourke

Source :

Respiratory research [ 1465-993X ] ; 2014.

RBID : pubmed:24621080

English descriptors

KwdEn :
- Adrenergic beta-Agonists (pharmacology), Animals, Bronchodilator Agents (pharmacology), Chloroquine (pharmacology), Lung (drug effects), Lung (physiology), Male, Mice, Mice, Inbred BALB C, Organ Culture Techniques, Rosiglitazone, Thiazolidinediones (pharmacology).
MESH :
- chemical , pharmacology : Adrenergic beta-Agonists, Bronchodilator Agents, Chloroquine, Thiazolidinediones.
- drug effects : Lung.
- physiology : Lung.
- Animals, Male, Mice, Mice, Inbred BALB C, Organ Culture Techniques, Rosiglitazone.

Abstract

Current therapy for relieving bronchoconstriction may be ineffective in severe asthma, particularly in the small airways. The aim of this study was to further characterise responses to the recently identified novel bronchodilators rosiglitazone (RGZ) and chloroquine (CQ) under conditions where β-adrenoceptor agonist efficacy was limited or impaired in mouse small airways within lung slices.

DOI: 10.1186/1465-9921-15-29
PubMed: 24621080

Links to Exploration step

pubmed:24621080

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rosiglitazone is a superior bronchodilator compared to chloroquine and β-adrenoceptor agonists in mouse lung slices.</title>
<author><name sortKey="Donovan, Chantal" sort="Donovan, Chantal" uniqKey="Donovan C" first="Chantal" last="Donovan">Chantal Donovan</name>
</author>
<author><name sortKey="Simoons, Mirjam" sort="Simoons, Mirjam" uniqKey="Simoons M" first="Mirjam" last="Simoons">Mirjam Simoons</name>
</author>
<author><name sortKey="Esposito, James" sort="Esposito, James" uniqKey="Esposito J" first="James" last="Esposito">James Esposito</name>
</author>
<author><name sortKey="Ni Cheong, Jean" sort="Ni Cheong, Jean" uniqKey="Ni Cheong J" first="Jean" last="Ni Cheong">Jean Ni Cheong</name>
</author>
<author><name sortKey="Fitzpatrick, Meaghan" sort="Fitzpatrick, Meaghan" uniqKey="Fitzpatrick M" first="Meaghan" last="Fitzpatrick">Meaghan Fitzpatrick</name>
</author>
<author><name sortKey="Bourke, Jane Elizabeth" sort="Bourke, Jane Elizabeth" uniqKey="Bourke J" first="Jane Elizabeth" last="Bourke">Jane Elizabeth Bourke</name>
<affiliation><nlm:affiliation>Lung Health Research Centre, Department of Pharmacology and Therapeutics, University of Melbourne, Parkville, VIC 3010, Australia. jane.bourke@unimelb.edu.au.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:24621080</idno>
<idno type="pmid">24621080</idno>
<idno type="doi">10.1186/1465-9921-15-29</idno>
<idno type="wicri:Area/PubMed/Corpus">000301</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000301</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Rosiglitazone is a superior bronchodilator compared to chloroquine and β-adrenoceptor agonists in mouse lung slices.</title>
<author><name sortKey="Donovan, Chantal" sort="Donovan, Chantal" uniqKey="Donovan C" first="Chantal" last="Donovan">Chantal Donovan</name>
</author>
<author><name sortKey="Simoons, Mirjam" sort="Simoons, Mirjam" uniqKey="Simoons M" first="Mirjam" last="Simoons">Mirjam Simoons</name>
</author>
<author><name sortKey="Esposito, James" sort="Esposito, James" uniqKey="Esposito J" first="James" last="Esposito">James Esposito</name>
</author>
<author><name sortKey="Ni Cheong, Jean" sort="Ni Cheong, Jean" uniqKey="Ni Cheong J" first="Jean" last="Ni Cheong">Jean Ni Cheong</name>
</author>
<author><name sortKey="Fitzpatrick, Meaghan" sort="Fitzpatrick, Meaghan" uniqKey="Fitzpatrick M" first="Meaghan" last="Fitzpatrick">Meaghan Fitzpatrick</name>
</author>
<author><name sortKey="Bourke, Jane Elizabeth" sort="Bourke, Jane Elizabeth" uniqKey="Bourke J" first="Jane Elizabeth" last="Bourke">Jane Elizabeth Bourke</name>
<affiliation><nlm:affiliation>Lung Health Research Centre, Department of Pharmacology and Therapeutics, University of Melbourne, Parkville, VIC 3010, Australia. jane.bourke@unimelb.edu.au.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Respiratory research</title>
<idno type="eISSN">1465-993X</idno>
<imprint><date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adrenergic beta-Agonists (pharmacology)</term>
<term>Animals</term>
<term>Bronchodilator Agents (pharmacology)</term>
<term>Chloroquine (pharmacology)</term>
<term>Lung (drug effects)</term>
<term>Lung (physiology)</term>
<term>Male</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Organ Culture Techniques</term>
<term>Rosiglitazone</term>
<term>Thiazolidinediones (pharmacology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Adrenergic beta-Agonists</term>
<term>Bronchodilator Agents</term>
<term>Chloroquine</term>
<term>Thiazolidinediones</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Lung</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Lung</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Male</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Organ Culture Techniques</term>
<term>Rosiglitazone</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Current therapy for relieving bronchoconstriction may be ineffective in severe asthma, particularly in the small airways. The aim of this study was to further characterise responses to the recently identified novel bronchodilators rosiglitazone (RGZ) and chloroquine (CQ) under conditions where β-adrenoceptor agonist efficacy was limited or impaired in mouse small airways within lung slices.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24621080</PMID>
<DateCompleted><Year>2014</Year>
<Month>10</Month>
<Day>06</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>12</Month>
<Day>02</Day>
</DateRevised>
<Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1465-993X</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>15</Volume>
<PubDate><Year>2014</Year>
<Month>Mar</Month>
<Day>12</Day>
</PubDate>
</JournalIssue>
<Title>Respiratory research</Title>
<ISOAbbreviation>Respir. Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Rosiglitazone is a superior bronchodilator compared to chloroquine and β-adrenoceptor agonists in mouse lung slices.</ArticleTitle>
<Pagination><MedlinePgn>29</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1186/1465-9921-15-29</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Current therapy for relieving bronchoconstriction may be ineffective in severe asthma, particularly in the small airways. The aim of this study was to further characterise responses to the recently identified novel bronchodilators rosiglitazone (RGZ) and chloroquine (CQ) under conditions where β-adrenoceptor agonist efficacy was limited or impaired in mouse small airways within lung slices.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Relaxation to RGZ and CQ was assessed following submaximal methacholine (MCh) pre-contraction, in slices treated overnight with either RGZ, CQ or albuterol (ALB) (to induce β-adrenoceptor desensitization), and in slices treated with caffeine/ryanodine in which contraction is associated with increases in Ca2+ sensitivity in the absence of contractile agonist-induced Ca2+ oscillations. Furthermore, the effects of RGZ, CQ, ALB and isoproterenol (ISO) on the initiation and development of methacholine-induced contraction were also compared.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">RGZ and CQ, but not ALB or ISO, elicited complete relaxation with increasing MCh pre-contraction and maintained their potency and efficacy following β-adrenoceptor desensitization. RGZ, CQ and ALB maintained efficacy following overnight incubation with RGZ or CQ. Relaxation responses to all dilators were generally maintained but delayed after caffeine/ryanodine. Pre-treatment with RGZ, but not CQ, ALB or ISO, reduced MCh potency.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study demonstrates the superior effectiveness of RGZ in comparison to CQ and β-adrenoceptor agonists as a dilator of mouse small airways. Further investigation of the mechanisms underlying the relatively greater efficacy of RGZ under these conditions are warranted and should be extended to include studies in human asthmatic airways.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Donovan</LastName>
<ForeName>Chantal</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Simoons</LastName>
<ForeName>Mirjam</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Esposito</LastName>
<ForeName>James</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ni Cheong</LastName>
<ForeName>Jean</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Fitzpatrick</LastName>
<ForeName>Meaghan</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Bourke</LastName>
<ForeName>Jane Elizabeth</ForeName>
<Initials>JE</Initials>
<AffiliationInfo><Affiliation>Lung Health Research Centre, Department of Pharmacology and Therapeutics, University of Melbourne, Parkville, VIC 3010, Australia. jane.bourke@unimelb.edu.au.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2014</Year>
<Month>03</Month>
<Day>12</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Respir Res</MedlineTA>
<NlmUniqueID>101090633</NlmUniqueID>
<ISSNLinking>1465-9921</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000318">Adrenergic beta-Agonists</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001993">Bronchodilator Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D045162">Thiazolidinediones</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>05V02F2KDG</RegistryNumber>
<NameOfSubstance UI="D000077154">Rosiglitazone</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>886U3H6UFF</RegistryNumber>
<NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000318" MajorTopicYN="N">Adrenergic beta-Agonists</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001993" MajorTopicYN="N">Bronchodilator Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009924" MajorTopicYN="N">Organ Culture Techniques</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000077154" MajorTopicYN="N">Rosiglitazone</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045162" MajorTopicYN="N">Thiazolidinediones</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year>
<Month>01</Month>
<Day>16</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2014</Year>
<Month>02</Month>
<Day>25</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2014</Year>
<Month>3</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2014</Year>
<Month>3</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2014</Year>
<Month>10</Month>
<Day>7</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">24621080</ArticleId>
<ArticleId IdType="pii">1465-9921-15-29</ArticleId>
<ArticleId IdType="doi">10.1186/1465-9921-15-29</ArticleId>
<ArticleId IdType="pmc">PMC3995634</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Am J Physiol Lung Cell Mol Physiol. 2012 Aug 15;303(4):L304-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22683571</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2011 Jul;17(7):776</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21738151</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2010 Nov;16(11):1299-304</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20972434</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur Respir J. 1999 Aug;14(2):283-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10515402</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Physiol Lung Cell Mol Physiol. 2006 Aug;291(2):L208-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16461427</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Physiol. 2005 Jun;125(6):535-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15928401</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Respir Crit Care Med. 2001 Oct 15;164(8 Pt 1):1487-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11704601</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur Respir Rev. 2011 Mar;20(119):23-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21357889</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Respir Cell Mol Biol. 2014 Apr;50(4):748-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24188042</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drug Saf. 2004;27(10):689-715</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15350154</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pulm Pharmacol Ther. 2008;21(1):1-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17169595</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Physiol Lung Cell Mol Physiol. 2002 Jun;282(6):L1161-78</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12003770</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Respir Cell Mol Biol. 2011 Nov;45(5):1069-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21642585</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Allergy. 2007 Feb;62(2):134-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17298421</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Respir Crit Care Med. 1998 Nov;158(5 Pt 3):S123-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9817735</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Physiol Lung Cell Mol Physiol. 2012 Dec 1;303(11):L956-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22962016</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Pharmacol Exp Ther. 1992 Apr;261(1):258-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1313869</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PPAR Res. 2012;2012:809164</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22966222</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Trends Pharmacol Sci. 2008 Jul;29(7):340-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18514920</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Pharmacol Exp Ther. 2005 Sep;314(3):995-1001</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15937152</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Biol. 2013;11(3):e1001501</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23472053</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur Respir J. 1998 Nov;12(5):1209-18</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9864023</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Thorax. 1993 Feb;48(2):130-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8493625</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pulm Pharmacol Ther. 2014 Jun;28(1):68-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24291048</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2013;8(9):e74101</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24040180</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Pharmacol. 1990 Jan;99(1):131-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2158831</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pulm Pharmacol Ther. 2013 Feb;26(1):112-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22634112</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Pharmacol. 2014 Feb;171(3):646-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24117140</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Pharmacol. 2011 Jun;163(3):521-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21306583</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Opin Ther Targets. 2013 Jun;17(6):721-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23577615</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am Rev Respir Dis. 1992 Jul;146(1):132-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1378252</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Pharmacol. 1985 May;85(1):29-36</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2411319</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Respir Crit Care Med. 1998 Nov;158(5 Pt 3):S146-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9817738</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2012 May;18(5):648-50; author reply 650-1</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22561814</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Pharmacol. 2013 Jun;13(3):324-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23639507</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Allergy Clin Immunol. 2008 Oct;122(4):734-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18774166</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2011 Jul;17(7):775</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21738149</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur Respir J. 2013 Jul;42(1):65-78</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23222870</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Exp Allergy. 2003 Jul;33(7):887-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12859443</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Respirology. 2004 Nov;9(4):448-57</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15612955</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pulm Pharmacol. 1994 Oct;7(5):293-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7626915</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Respir Cell Mol Biol. 2008 May;38(5):524-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18063837</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000301 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000301 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:24621080
   |texte=   Rosiglitazone is a superior bronchodilator compared to chloroquine and β-adrenoceptor agonists in mouse lung slices.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:24621080" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a ChloroquineV1

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021

	Serveur d'exploration Chloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Chloroquine

Rosiglitazone is a superior bronchodilator compared to chloroquine and β-adrenoceptor agonists in mouse lung slices.

Rosiglitazone is a superior bronchodilator compared to chloroquine and β-adrenoceptor agonists in mouse lung slices.

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki